Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 85 |
| Updated: | 1/23/2019 |
| Start Date: | January 23, 2012 |
| End Date: | May 2019 |
| Contact: | Mary K Jackson |
| Email: | mary.k.jackson@ucdenver.edu |
| Phone: | 303-724-1650 |
Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung and Other Thoracic Cancers
The mechanisms of sensitivity and resistance to oncogene-targeted therapy can be determined
from tumor tissue or tumor cell lines derived from available archival samples and/or from
standard-of-care re-biopsy upon suspected tumor progression.
from tumor tissue or tumor cell lines derived from available archival samples and/or from
standard-of-care re-biopsy upon suspected tumor progression.
To identify baseline and treatment-related somatic changes in the tumor tissue from patients
with lung and other thoracic cancers. To estimate the proportion of patients that subsequent
therapy is altered based on the information acquired from such biopsies.
with lung and other thoracic cancers. To estimate the proportion of patients that subsequent
therapy is altered based on the information acquired from such biopsies.
Inclusion Criteria:
1. Patients undergoing investigation or treatment for thoracic cancers with
oncogene-targeted therapies
2. Aged 18 years or older
3. Either a) have suspected tumor progression or other condition that dictates a
standard-of-care palliative, therapeutic, or diagnostic intervention including but not
limited to procedures such as bronchoscopic biopsy, computed tomography (CT) or
ultra-sound (US)-guided biopsy, thoracentesis, video assisted thoracoscopic (VATS)
pleurodesis, lobectomy, adrenalectomy or pleural catheter placement, providing tumor
specimen appropriate molecular analysis or b) have previously had biopsy/surgical
intervention with tumor tissue at University of Colorado or an outside institution
available for medullar analysis.
4. Patients must have the ability to understand and willingness to sign an informed
consent document.
Exclusion Criteria:
We found this trial at
1
site
Aurora, Colorado 80045
Principal Investigator: Robert C Doebele, MD,Ph.D
Phone: 303-724-1650
Click here to add this to my saved trials
